Tamoxifen—What Next?

Tamoxifen—What Next? William J. Gradishar Oncologist 2004; 9: 378-384 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Understand the current treatment options available for postmenopausal women with breast cancer. Explain the impact of new clinical trial data on the existing schedule of endocrine therapy. Describe the future direction of endocrine therapy for advanced breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: July 21, 2004 Most Recent Review: October 13, 2005* Most Recent Update: July 21, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.